PD-L1 expression and prognostic impact in glioblastoma

Neuro-oncology
Edjah K NduomAmy B Heimberger

Abstract

Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact. Using immunohistochemical analysis, we measured the incidence of PD-L1 expression in 94 patients with GBM. We categorized our results according to the total number of PD-L1-expressing cells within the GBMs and then validated this finding in ex vivo GBM flow cytometry with further analysis of the T cell populations. We then evaluated the association between PD-L1 expression and median survival time using the protein expression datasets and mRNA from The Cancer Genome Atlas. The median percentage of PD-L1-expressing cells in GBM by cell surface staining is 2.77% (range: 0%-86.6%; n = 92), which is similar to the percentage found by ex vivo flow cytometry. The majority of GBM patients (61%) had tumors with at least 1% or more PD-L1-positive cells, and 38% had at least 5% or greater PD-L1 expressi...Continue Reading

References

Jul 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yvette E LatchmanArlene H Sharpe
Jul 1, 2008·Molecular Immunology·Manish J ButteArlene H Sharpe
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amy B HeimbergerGregory N Fuller
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohamed Abou-GhazalAmy B Heimberger
Feb 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Oezcan TalayJianzhu Chen
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun WeiAmy B Heimberger
Jul 30, 2010·Neuro-oncology·Adam WuAmy B Heimberger
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Jun 24, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alison M PatersonArlene H Sharpe
Feb 1, 2012·The Cancer Journal·Alissa A ThomasCamilo E Fadul
Apr 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Orin BlochAndrew T Parsa
Apr 30, 2013·Journal of Leukocyte Biology·Andrew M Intlekofer, Craig B Thompson
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Aug 30, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yawei LiuShohreh Issazadeh-Navikas
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Oct 23, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberY Ann Chen
Nov 13, 2013·Laboratory Investigation; a Journal of Technical Methods and Pathology·Vamsidhar VelchetiDavid L Rimm
Jan 11, 2014·Cancer Immunology Research·Tiffany DoucetteAmy B Heimberger
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Derek A WainwrightMaciej S Lesniak
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Sep 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T K ChoueiriS Signoretti
Oct 29, 2014·British Journal of Cancer·A D'InceccoF Cappuzzo
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Jan 31, 2015·The New England Journal of Medicine·Francis S Collins, Harold Varmus
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn

❮ Previous
Next ❯

Citations

Jul 30, 2016·Oncoimmunology·Tiffany R HodgesAmy B Heimberger
Dec 8, 2015·Journal of Neuro-oncology·Jonathan B LamanoOrin Bloch
Mar 15, 2016·Frontiers in Surgery·Seyed-Mostafa RazaviGordon Li
Dec 15, 2015·Neuro-oncology·Jun WeiAmy B Heimberger
Jun 3, 2016·Expert Review of Anticancer Therapy·Nicole A P LiebermanCourtney A Crane
Jul 3, 2016·Neuro-oncology·Sarah T GarberAmy B Heimberger
Aug 19, 2016·Neuro-oncology·Anna S Berghoff, Matthias Preusser
Jul 28, 2016·Cancer Immunology, Immunotherapy : CII·Michael PlattenTheresa Bunse
Oct 16, 2016·Magnetic Resonance Imaging Clinics of North America·Travis C SalzilloPratip K Bhattacharya
Dec 22, 2016·Immunotherapy·Shunichiro KuramitsuAtsushi Natsume
Mar 18, 2017·Current Oncology Reports·Aaron C TanMustafa Khasraw
Mar 17, 2017·World Neurosurgery·Alice L HungMichael Lim
Apr 4, 2017·Current Opinion in Neurology·David A ReardonJohn H Sampson
May 13, 2017·Nature Reviews. Neurology·Michael WellerJohn H Sampson
May 26, 2017·Neurologia Medico-chirurgica·Eiichi IshikawaAkira Matsumura
May 16, 2017·Histopathology·Deborah SaraggiMassimo Rugge
Jul 14, 2017·International Journal of Molecular Sciences·Hyosun ChoChang Wook Kim
Jul 7, 2017·International Journal of Cancer. Journal International Du Cancer·Joost DejaegherSteven De Vleeschouwer
Feb 8, 2018·Journal of Neuropathology and Experimental Neurology·Miriam E WildemanM Beatriz S Lopes
Mar 14, 2018·Expert Review of Anticancer Therapy·Brooke L PrinzingGiedre Krenciute
Mar 14, 2018·Science Advances·Franz L RicklefsE Antonio Chiocca
Nov 11, 2017·Frontiers in Immunology·Matteo MassaraRaffaella Bonecchi
Dec 20, 2017·Journal for Immunotherapy of Cancer·Samantha N ReissChristian Grommes
Oct 17, 2017·Neuro-oncology·Felix Sahm, Antje Wick
Feb 10, 2018·Immunotherapy·Neha KamranMaria G Castro
Aug 4, 2018·Journal of Neuro-oncology·Rimas V LukasJoachim Baehring
Mar 13, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Bozena KaminskaBartlomiej Gielniewski
Jan 27, 2019·Journal of Pediatric Hematology/oncology·Hamza S GorsiJohn R Crawford
May 14, 2019·Expert Review of Molecular Diagnostics·Ke MaYuyang Zhang
Sep 14, 2018·Cardiovascular and Interventional Radiology·A DigkliaA Denys
Aug 9, 2017·Current Treatment Options in Oncology·Russell MaxwellMichael Lim
Nov 18, 2017·Journal of Neuro-oncology·Kyu Sang LeeGheeyoung Choe
Oct 11, 2019·Drugs·Rimas V LukasAdam M Sonabend
Sep 20, 2019·CNS Oncology·Nawal ShaikhRimas V Lukas
Oct 7, 2017·Current Opinion in Neurology·Iris MildenbergerMichael Platten
Sep 15, 2017·American Journal of Clinical Oncology·Elizabeth ReznikA Gabriella Wernicke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
R A DroeserLuigi Tornillo
Current Treatment Options in Oncology
Douglas B JohnsonLeora Horn
© 2021 Meta ULC. All rights reserved